ADCYAP1R1 and migraine disorder: Evaluation of the anti-PACAP antibody efficacy is ongoing, but the anti-PAC1 receptor antibody exhibited no significant clinical efficacy over placebo for the treatment of migraine, resulting in uncertainty around the role PAC1 plays in migraine [19].